Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study.

Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, Chen Y, Su Y, Myers AJ, Hardy J, Paul Vonsattel J, Younkin SG, Bennett DA, De Jager PL, Larson EB, Crane PK, Keene CD, Kamboh MI, Kofler JK, Duque L, Gilbert JR, Gwirtsman HE, Buxbaum JD, Dickson DW, Frosch MP, Ghetti BF, Lunetta KL, Wang LS, Hyman BT, Kukull WA, Foroud T, Haines JL, Mayeux RP, Pericak-Vance MA, Schneider JA, Trojanowski JQ, Farrer LA, Schellenberg GD, Beecham GW, Montine TJ, Jun GR, Alzheimer’s Disease Genetics Consortium. · 2020

Read Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. by Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, Chen Y, Su Y, Myers AJ, Hardy J, Paul Vonsattel J, Younkin SG, Bennett DA, De Jager PL, Larson EB, Crane PK, Keene CD, Kamboh MI, Kofler JK, Duque L, Gilbert JR, Gwirtsman HE, Buxbaum JD, Dickson DW, Frosch MP, Ghetti BF, Lunetta KL, Wang LS, Hyman BT, Kukull WA, Foroud T, Haines JL, Mayeux RP, Pericak-Vance MA, Schneider JA, Trojanowski JQ, Farrer LA, Schellenberg GD, Beecham GW, Montine TJ, Jun GR, Alzheimer’s Disease Genetics Consortium. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6997393.txt.

Introduction

Reiman and co-authors show that people with two copies of a protective gene variant almost never develop Alzheimer's dementia. Their study appeared in Nature Communications. The APOE gene shapes Alzheimer's risk. Its E4 version raises risk with each copy, while E2 lowers it. Whether two E2 copies give special protection was unknown.

The team built odds from more than 5,000 cases and controls, all checked clinically and by brain examination after death. People with APOE2/2 had far lower dementia odds than those with one E2, and exceptionally lower odds than E4 homozygotes. The gene-dose effect ran stronger in brain-confirmed cases than in a comparison set of over 24,000 unconfirmed ones. Finding how APOE variants protect or harm, the authors argue, could transform prevention.

Catalog record

CREATORReiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, Chen Y, Su Y, Myers AJ, Hardy J, Paul Vonsattel J, Younkin SG, Bennett DA, De Jager PL, Larson EB, Crane PK, Keene CD, Kamboh MI, Kofler JK, Duque L, Gilbert JR, Gwirtsman HE, Buxbaum JD, Dickson DW, Frosch MP, Ghetti BF, Lunetta KL, Wang LS, Hyman BT, Kukull WA, Foroud T, Haines JL, Mayeux RP, Pericak-Vance MA, Schneider JA, Trojanowski JQ, Farrer LA, Schellenberg GD, Beecham GW, Montine TJ, Jun GR, Alzheimer’s Disease Genetics Consortium.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6997393

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study By Eric M. Reiman, Joseph F. Arboleda-Velasquez, Yakeel T. Quiroz, Matthew J. Huentelman, Thomas G. Beach, Richard J. Caselli, Yinghua Chen, Yi Su, Amanda J. Myers, John Hardy, Jean Paul Vonsattel, Steven G. Younkin Published in: Nature Communications DOI: 10.1038/s41467-019-14279-8 ABSTRACT Each additional copy of the apolipoprotein E4 (APOE4) allele is associated with a higher risk of Alzheimer’s dementia, while the APOE2 allele is associated with a lower risk of Alzheimer’s dementia, it is not yet known whether APOE2 homozygotes have a particularly low risk. We generated Alzheimer’s dementia odds ratios and other findings in more than 5,000 clinically characterized and neuropathologically characterized Alzheimer’s dementia cases and controls. APOE2/2 was associated with a low Alzheimer’s dementia odds ratios compared to APOE2/3 and 3/3, and an exceptionally low odds ratio compared to APOE4/4, and the impact of APOE2 and APOE4 gene dose was significantly greater in the neuropathologically confirmed group than in more than 24,000 neuropathologically unconfirmed cases and controls. Finding and targeting the factors by which APOE and its variants influence Alzheimer’s disease could have a major impact on the understanding, treatment and prevention of the disease. INTRODUCTION Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4). Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk, while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4. It remains to be clarified whether APOE2 homozygotes have a lower odd than persons with the APOE2/3 genotype—a question we sought to address in an unusually large number of clinically and neuropathologically classified Alzheimer’s dementia cases and controls. We recently discovered two copies of the rare APOE3 Christchurch (APOE3ch [Arg136→Ser]) mutation, located in the ApoE protein’s low-density lipoprotein receptor (LDLR) binding region, in an amyloid-β42 (Aβ42)-overproducing presenilin 1 (PSEN1) E280A mutation carrier from the world’s largest autosomal dominant AD (ADAD) kindred who did not develop mild cognitive impairment (MCI) until her 70s, nearly three decades after her kindred’s mean age at MCI onset5. Using positron-emission tomography (PET) to compare her to other PSEN1 E280A mutation carriers with MCI, she had the greatest fibrillar amyloid-β (Aβ) burden (the major constituent of neuritic plaques), limited paired helical filament (PHF) tau (neurofibrillary tangle) burden, and minimal glucose hypometabolism in brain regions preferentially affected by AD. Like 5–10% of APOE2 homozygotes, she also had hyperlipoproteinemia Type III, reflecting reduced binding of the ApoE to LDLR5,6. Like the ApoE2 protein, the ApoEch protein was associated with less Aβ42 aggregation than the ApoE3 protein in vitro5,7. Since an APOE2 homozygote with an ADAD mutation did not have a significantly delayed clinical onset of ADAD, we postulated that homozygosity for APOEch may be more protective than homozygosity for APOE2, but that APOE2 homozygotes might still have an exceptionally low risk of late-onset Alzheimer’s dementia. We also postulated that APOE2 and APOE4 allelic dose would have a more profound impact on Alzheimer’s dementia odds ratios (ORs) in neuropathologically confirmed than in unconfirmed cases and controls due to the exclusion of clinically diagnosed cases who did not meet the neuropathological criteria for AD and unimpaired controls who met the criteria for AD, since misclassified cases and controls could dilute and/or bias OR estimates in the unconfirmed group. This possibility has remained unaddressed, because case–control studies without neuropathological or biomarker assessments of AD may have underestimated the impact of APOE genotypes on Alzheimer’s dementia ORs due to the confounding effects of APOE genotypes on the percentages of neuropathologically misclassified cases and controls8–10. In fact, APOE4 non-carriers tend to be misclassified more frequently, such that 13% of APOE4 carriers versus 37% of non-carriers with the clinical diagnosis of mild-to-moderate Alzheimer’s dementia do not meet neuropathological criteria for AD8. Also, previous studies of clinically and neuropathologically characterized cases and controls may have been too small to demonstrate that APOE2 homozygotes have an even lower OR than the relatively low-risk APOE2/3 group due to the paucity of APOE2 homozygotes, who comprise <1% of the general population1,4. This study sought to establish that APOE2 homozygotes have an exceptionally low likelihood of Alzheimer’s dementia, demonstrate the value of AD risk assessments in clinically and neuropathologically characterized cases and controls, and underscore the impact of different APOE genotypes on Alzheimer’s dementia ORs relative to the lowest risk APOE2/2 and highest risk APOE4/4 genotypes. More generally, it sought to highlight the impact of discovering and targeting the mechanism by which APOE variants account for differential risk could have on the understanding, treatment, and prevention of AD, including those interventions that might prevent both the initial development of AD pathology and the subsequent development of dementia. RESULTS Neuropathologically confirmed and unconfirmed groups Supplementary Table 1 shows the number of Alzheimer’s dementia cases and cognitively unimpaired controls for each APOE genotype in (a) the Alzheimer’s Disease Genetics Consortium (ADGC’s) clinically characterized and neuropathologically confirmed autopsy group, (b) its clinically characterized but neuropathologically unconfirmed clinical group, and (c) the combined neuropathological and clinical group. The 5007 participants in the neuropathologically confirmed cohort included 4018 AD dementia cases and 989 cognitively unimpaired and neuropathologically unaffected controls. The 23,857 participants in the clinically classified but neuropathologically unconfirmed cohort included 10,430 probable AD dementia cases and 13,426 cognitively unimpaired controls. The 28,864 participants in the combined group included 14,448 cases and 14,416 controls. Supplementary Table 2 summarizes ages at dementia onset in the cases, ages at last clinical exam in the cases, and ages at death in the neuropathologically confirmed autopsy cohort. Alzheimer’s dementia ORs Table 1 and Supplementary Table 3 show Alzheimer’s dementia ORs for each APOE genotype and allelic doses (i.e., the number of APOE2 alleles in APOE4 non-carriers and the number of APOE4 alleles in APOE2 non-carriers) before and after adjustment for age and sex in the neuropathologically confirmed and unconfirmed groups before and after adjustment for age and sex, compared to the common APOE3/3 genotype. ORs associated with APOE2 allelic dose in APOE4 non-carriers (APOE2/2 < 2/3 < 3/3) and APOE4 allelic dose in APOE2 non-carriers (APOE4/4 > 3/4 > 3/3) were generated using allelic association tests in an additive genetic model. As discussed below, APOE2/2, APOE2/3, and APOE2 allelic dose ORs were significantly lower, and APOE3/4, APOE4/4, and APOE4 allelic dose ORs were significantly higher, in the neuropathologically confirmed group than in the unconfirmed group. While ORs for the other APOE genotypes were similar to those that we had reported in a small number of cases and controls, the number of APOE2 homozygotes in the earlier study was too small to provide an accurate OR estimate1,11. Table 2 shows Alzheimer’s dementia ORs for each APOE genotype compared to the relatively low-risk APOE2/3 and highest risk APOE4 genotypes in the neuropathologically confirmed cohort. As discussed below, these ORs permitted us to confirm our primary hypothesis that

Read the complete text